nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Lofexidine—HTR1A—stomach cancer	0.0151	1	CrCbGaD
Apraclonidine—Mental disorder—Docetaxel—stomach cancer	0.00128	0.00182	CcSEcCtD
Apraclonidine—Somnolence—Fluorouracil—stomach cancer	0.00128	0.00182	CcSEcCtD
Apraclonidine—Mediastinal disorder—Capecitabine—stomach cancer	0.00127	0.00182	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—stomach cancer	0.00127	0.00181	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—stomach cancer	0.00127	0.00181	CcSEcCtD
Apraclonidine—Erythema—Docetaxel—stomach cancer	0.00127	0.00181	CcSEcCtD
Apraclonidine—Arrhythmia—Capecitabine—stomach cancer	0.00126	0.0018	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—stomach cancer	0.00126	0.0018	CcSEcCtD
Apraclonidine—Dysgeusia—Docetaxel—stomach cancer	0.00125	0.00177	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.00124	0.00177	CcSEcCtD
Apraclonidine—Mental disorder—Capecitabine—stomach cancer	0.00124	0.00177	CcSEcCtD
Apraclonidine—Feeling abnormal—Irinotecan—stomach cancer	0.00124	0.00176	CcSEcCtD
Apraclonidine—Erythema—Capecitabine—stomach cancer	0.00123	0.00175	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—stomach cancer	0.00123	0.00175	CcSEcCtD
Apraclonidine—Pain—Fluorouracil—stomach cancer	0.00123	0.00175	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Irinotecan—stomach cancer	0.00123	0.00175	CcSEcCtD
Apraclonidine—Dysgeusia—Capecitabine—stomach cancer	0.00121	0.00172	CcSEcCtD
Apraclonidine—Abdominal pain—Irinotecan—stomach cancer	0.00119	0.00169	CcSEcCtD
Apraclonidine—Feeling abnormal—Fluorouracil—stomach cancer	0.00118	0.00169	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—stomach cancer	0.00118	0.00168	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—stomach cancer	0.00117	0.00167	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—stomach cancer	0.00117	0.00167	CcSEcCtD
Apraclonidine—Vision blurred—Capecitabine—stomach cancer	0.00116	0.00165	CcSEcCtD
Apraclonidine—Ill-defined disorder—Capecitabine—stomach cancer	0.00114	0.00163	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—stomach cancer	0.00114	0.00163	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—stomach cancer	0.00114	0.00162	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—stomach cancer	0.00114	0.00162	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—stomach cancer	0.00112	0.0016	CcSEcCtD
Apraclonidine—Malaise—Capecitabine—stomach cancer	0.00111	0.00158	CcSEcCtD
Apraclonidine—Hypersensitivity—Irinotecan—stomach cancer	0.00111	0.00158	CcSEcCtD
Apraclonidine—Syncope—Capecitabine—stomach cancer	0.0011	0.00157	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—stomach cancer	0.0011	0.00156	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—stomach cancer	0.0011	0.00156	CcSEcCtD
Apraclonidine—Palpitations—Capecitabine—stomach cancer	0.00109	0.00155	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—stomach cancer	0.00108	0.00154	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—stomach cancer	0.00108	0.00154	CcSEcCtD
Apraclonidine—Asthenia—Irinotecan—stomach cancer	0.00108	0.00153	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.00108	0.00153	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—stomach cancer	0.00107	0.00152	CcSEcCtD
Apraclonidine—Hypersensitivity—Fluorouracil—stomach cancer	0.00106	0.00151	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—stomach cancer	0.00106	0.00151	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—stomach cancer	0.00105	0.0015	CcSEcCtD
Apraclonidine—Chest pain—Capecitabine—stomach cancer	0.00105	0.00149	CcSEcCtD
Apraclonidine—Myalgia—Capecitabine—stomach cancer	0.00105	0.00149	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—stomach cancer	0.00104	0.00149	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.00104	0.00148	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—stomach cancer	0.00104	0.00148	CcSEcCtD
Apraclonidine—Discomfort—Capecitabine—stomach cancer	0.00104	0.00148	CcSEcCtD
Apraclonidine—Infection—Docetaxel—stomach cancer	0.00103	0.00147	CcSEcCtD
Apraclonidine—Diarrhoea—Irinotecan—stomach cancer	0.00103	0.00146	CcSEcCtD
Apraclonidine—Dry mouth—Capecitabine—stomach cancer	0.00103	0.00146	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—stomach cancer	0.00102	0.00145	CcSEcCtD
Apraclonidine—Pruritus—Fluorouracil—stomach cancer	0.00102	0.00145	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—stomach cancer	0.00102	0.00145	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—stomach cancer	0.00102	0.00145	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—stomach cancer	0.00101	0.00145	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—stomach cancer	0.00101	0.00144	CcSEcCtD
Apraclonidine—Oedema—Capecitabine—stomach cancer	0.001	0.00143	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—stomach cancer	0.001	0.00143	CcSEcCtD
Apraclonidine—Infection—Capecitabine—stomach cancer	0.000998	0.00142	CcSEcCtD
Apraclonidine—Dizziness—Irinotecan—stomach cancer	0.000993	0.00141	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—stomach cancer	0.000988	0.00141	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—stomach cancer	0.000987	0.00141	CcSEcCtD
Apraclonidine—Nervous system disorder—Capecitabine—stomach cancer	0.000985	0.0014	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—stomach cancer	0.000985	0.0014	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—stomach cancer	0.000984	0.0014	CcSEcCtD
Apraclonidine—Diarrhoea—Fluorouracil—stomach cancer	0.000984	0.0014	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—stomach cancer	0.000978	0.00139	CcSEcCtD
Apraclonidine—Skin disorder—Capecitabine—stomach cancer	0.000976	0.00139	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—stomach cancer	0.000971	0.00138	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—stomach cancer	0.000955	0.00136	CcSEcCtD
Apraclonidine—Vomiting—Irinotecan—stomach cancer	0.000955	0.00136	CcSEcCtD
Apraclonidine—Dizziness—Fluorouracil—stomach cancer	0.000951	0.00135	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—stomach cancer	0.00095	0.00135	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—stomach cancer	0.000949	0.00135	CcSEcCtD
Apraclonidine—Dermatitis—Irinotecan—stomach cancer	0.000946	0.00135	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000946	0.00135	CcSEcCtD
Apraclonidine—Headache—Irinotecan—stomach cancer	0.000941	0.00134	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—stomach cancer	0.000939	0.00134	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—stomach cancer	0.000932	0.00133	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—stomach cancer	0.000928	0.00132	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—stomach cancer	0.000925	0.00132	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—stomach cancer	0.000923	0.00131	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—stomach cancer	0.000922	0.00131	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—stomach cancer	0.000921	0.00131	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—stomach cancer	0.000917	0.00131	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000916	0.0013	CcSEcCtD
Apraclonidine—Vomiting—Fluorouracil—stomach cancer	0.000914	0.0013	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—stomach cancer	0.000914	0.0013	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—stomach cancer	0.000912	0.0013	CcSEcCtD
Apraclonidine—Insomnia—Capecitabine—stomach cancer	0.000909	0.0013	CcSEcCtD
Apraclonidine—Dermatitis—Fluorouracil—stomach cancer	0.000906	0.00129	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—stomach cancer	0.000905	0.00129	CcSEcCtD
Apraclonidine—Paraesthesia—Capecitabine—stomach cancer	0.000902	0.00129	CcSEcCtD
Apraclonidine—Headache—Fluorouracil—stomach cancer	0.000901	0.00128	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—stomach cancer	0.000898	0.00128	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—stomach cancer	0.000898	0.00128	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000896	0.00128	CcSEcCtD
Apraclonidine—Dyspnoea—Capecitabine—stomach cancer	0.000896	0.00128	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—stomach cancer	0.000895	0.00128	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—stomach cancer	0.000894	0.00127	CcSEcCtD
Apraclonidine—Nausea—Irinotecan—stomach cancer	0.000892	0.00127	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—stomach cancer	0.000888	0.00127	CcSEcCtD
Apraclonidine—Pain—Docetaxel—stomach cancer	0.000888	0.00126	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—stomach cancer	0.000888	0.00126	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—stomach cancer	0.00088	0.00125	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—stomach cancer	0.000879	0.00125	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000868	0.00124	CcSEcCtD
Apraclonidine—Fatigue—Capecitabine—stomach cancer	0.000866	0.00123	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—stomach cancer	0.000864	0.00123	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—stomach cancer	0.000863	0.00123	CcSEcCtD
Apraclonidine—Constipation—Capecitabine—stomach cancer	0.000859	0.00122	CcSEcCtD
Apraclonidine—Pain—Capecitabine—stomach cancer	0.000859	0.00122	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—stomach cancer	0.000858	0.00122	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—stomach cancer	0.000855	0.00122	CcSEcCtD
Apraclonidine—Nausea—Fluorouracil—stomach cancer	0.000854	0.00122	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—stomach cancer	0.000852	0.00121	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—stomach cancer	0.00085	0.00121	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—stomach cancer	0.000849	0.00121	CcSEcCtD
Apraclonidine—Tension—Epirubicin—stomach cancer	0.000842	0.0012	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—stomach cancer	0.00084	0.0012	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—stomach cancer	0.000833	0.00119	CcSEcCtD
Apraclonidine—Feeling abnormal—Capecitabine—stomach cancer	0.000828	0.00118	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—stomach cancer	0.000827	0.00118	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—stomach cancer	0.000827	0.00118	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Capecitabine—stomach cancer	0.000822	0.00117	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—stomach cancer	0.000822	0.00117	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—stomach cancer	0.00082	0.00117	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—stomach cancer	0.000814	0.00116	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—stomach cancer	0.000808	0.00115	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—stomach cancer	0.000799	0.00114	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—stomach cancer	0.000796	0.00113	CcSEcCtD
Apraclonidine—Abdominal pain—Capecitabine—stomach cancer	0.000794	0.00113	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—stomach cancer	0.000794	0.00113	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—stomach cancer	0.00078	0.00111	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—stomach cancer	0.00078	0.00111	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—stomach cancer	0.000779	0.00111	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—stomach cancer	0.000777	0.00111	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000775	0.0011	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—stomach cancer	0.000774	0.0011	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—stomach cancer	0.000771	0.0011	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—stomach cancer	0.000771	0.0011	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—stomach cancer	0.000769	0.0011	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—stomach cancer	0.000765	0.00109	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—stomach cancer	0.000758	0.00108	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—stomach cancer	0.000748	0.00107	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—stomach cancer	0.000745	0.00106	CcSEcCtD
Apraclonidine—Infection—Methotrexate—stomach cancer	0.000743	0.00106	CcSEcCtD
Apraclonidine—Hypersensitivity—Capecitabine—stomach cancer	0.00074	0.00105	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—stomach cancer	0.000736	0.00105	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—stomach cancer	0.000734	0.00105	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—stomach cancer	0.000734	0.00105	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—stomach cancer	0.00073	0.00104	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—stomach cancer	0.00073	0.00104	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—stomach cancer	0.000727	0.00104	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000725	0.00103	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—stomach cancer	0.000722	0.00103	CcSEcCtD
Apraclonidine—Asthenia—Capecitabine—stomach cancer	0.000721	0.00103	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—stomach cancer	0.000716	0.00102	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—stomach cancer	0.000714	0.00102	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—stomach cancer	0.000712	0.00101	CcSEcCtD
Apraclonidine—Pruritus—Capecitabine—stomach cancer	0.000711	0.00101	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—stomach cancer	0.00071	0.00101	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—stomach cancer	0.000701	0.000999	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—stomach cancer	0.0007	0.000998	CcSEcCtD
Apraclonidine—Infection—Epirubicin—stomach cancer	0.000695	0.000991	CcSEcCtD
Apraclonidine—Diarrhoea—Capecitabine—stomach cancer	0.000688	0.00098	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—stomach cancer	0.000687	0.000978	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—stomach cancer	0.000686	0.000978	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000682	0.000971	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—stomach cancer	0.00068	0.000969	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—stomach cancer	0.000677	0.000964	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—stomach cancer	0.000676	0.000963	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—stomach cancer	0.000676	0.000963	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—stomach cancer	0.000672	0.000957	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000671	0.000956	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—stomach cancer	0.000668	0.000951	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—stomach cancer	0.000667	0.00095	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—stomach cancer	0.000665	0.000948	CcSEcCtD
Apraclonidine—Dizziness—Capecitabine—stomach cancer	0.000664	0.000947	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—stomach cancer	0.000661	0.000942	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—stomach cancer	0.00066	0.00094	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—stomach cancer	0.000654	0.000932	CcSEcCtD
Apraclonidine—Headache—Docetaxel—stomach cancer	0.00065	0.000926	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—stomach cancer	0.000648	0.000923	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000646	0.00092	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—stomach cancer	0.000645	0.000919	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—stomach cancer	0.000643	0.000917	CcSEcCtD
Apraclonidine—Pain—Methotrexate—stomach cancer	0.00064	0.000912	CcSEcCtD
Apraclonidine—Vomiting—Capecitabine—stomach cancer	0.000639	0.00091	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000638	0.000909	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—stomach cancer	0.000635	0.000905	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—stomach cancer	0.000633	0.000902	CcSEcCtD
Apraclonidine—Dermatitis—Capecitabine—stomach cancer	0.000633	0.000902	CcSEcCtD
Apraclonidine—Headache—Capecitabine—stomach cancer	0.00063	0.000897	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—stomach cancer	0.000629	0.000897	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—stomach cancer	0.000629	0.000896	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—stomach cancer	0.000624	0.000889	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—stomach cancer	0.000622	0.000887	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—stomach cancer	0.000616	0.000878	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—stomach cancer	0.000616	0.000878	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—stomach cancer	0.000612	0.000872	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000604	0.000861	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—stomach cancer	0.000604	0.00086	CcSEcCtD
Apraclonidine—Pain—Epirubicin—stomach cancer	0.000599	0.000853	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—stomach cancer	0.000599	0.000853	CcSEcCtD
Apraclonidine—Nausea—Capecitabine—stomach cancer	0.000597	0.000851	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—stomach cancer	0.000591	0.000843	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.00059	0.000841	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—stomach cancer	0.000586	0.000835	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—stomach cancer	0.000582	0.000829	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—stomach cancer	0.000577	0.000823	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—stomach cancer	0.000577	0.000822	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—stomach cancer	0.000576	0.000821	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—stomach cancer	0.000572	0.000816	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000559	0.000797	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—stomach cancer	0.000558	0.000796	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—stomach cancer	0.000554	0.000789	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—stomach cancer	0.000554	0.000789	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—stomach cancer	0.000553	0.000789	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—stomach cancer	0.000551	0.000785	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—stomach cancer	0.000537	0.000765	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—stomach cancer	0.000534	0.000761	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—stomach cancer	0.00053	0.000755	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—stomach cancer	0.000529	0.000754	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—stomach cancer	0.000516	0.000735	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—stomach cancer	0.000512	0.00073	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—stomach cancer	0.000512	0.000729	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—stomach cancer	0.000502	0.000716	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—stomach cancer	0.000495	0.000706	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—stomach cancer	0.000495	0.000705	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—stomach cancer	0.000479	0.000683	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—stomach cancer	0.000477	0.00068	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—stomach cancer	0.000476	0.000678	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—stomach cancer	0.000471	0.000671	CcSEcCtD
Apraclonidine—Headache—Methotrexate—stomach cancer	0.000469	0.000668	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—stomach cancer	0.000465	0.000662	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—stomach cancer	0.000463	0.00066	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—stomach cancer	0.000458	0.000653	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—stomach cancer	0.000445	0.000634	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—stomach cancer	0.000444	0.000633	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—stomach cancer	0.000443	0.000632	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—stomach cancer	0.000441	0.000628	CcSEcCtD
Apraclonidine—Headache—Epirubicin—stomach cancer	0.000439	0.000625	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—stomach cancer	0.000428	0.00061	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—stomach cancer	0.000416	0.000593	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—stomach cancer	0.000412	0.000587	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—stomach cancer	0.000408	0.000581	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—stomach cancer	0.000406	0.000578	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—stomach cancer	0.000385	0.000548	CcSEcCtD
Apraclonidine—ADRA1A—Signaling Pathways—ANXA1—stomach cancer	8.27e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HSPB1—stomach cancer	8.26e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGTR2—stomach cancer	8.26e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6R—stomach cancer	8.19e-05	0.000289	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BMP2—stomach cancer	8.17e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—F2R—stomach cancer	8.17e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—RHOA—stomach cancer	8.15e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—MAPK3—stomach cancer	8.12e-05	0.000287	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HBEGF—stomach cancer	8.04e-05	0.000284	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKR1C3—stomach cancer	8.04e-05	0.000284	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRB1—stomach cancer	8e-05	0.000283	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR1A—stomach cancer	7.95e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRB2—stomach cancer	7.94e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TYMS—stomach cancer	7.93e-05	0.00028	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GSTM1—stomach cancer	7.84e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—KRAS—stomach cancer	7.81e-05	0.000276	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PPP2R1A—stomach cancer	7.78e-05	0.000275	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—MAPK1—stomach cancer	7.73e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PRKCB—stomach cancer	7.7e-05	0.000272	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ANXA1—stomach cancer	7.68e-05	0.000271	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6R—stomach cancer	7.65e-05	0.00027	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RPS6—stomach cancer	7.65e-05	0.00027	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—RHOA—stomach cancer	7.61e-05	0.000269	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PRKCB—stomach cancer	7.52e-05	0.000266	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6ST—stomach cancer	7.49e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB1—stomach cancer	7.44e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRB2—stomach cancer	7.42e-05	0.000262	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—RHOA—stomach cancer	7.4e-05	0.000261	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ERCC2—stomach cancer	7.37e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—KRAS—stomach cancer	7.3e-05	0.000258	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PPP2R1A—stomach cancer	7.27e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SMAD4—stomach cancer	7.23e-05	0.000255	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—PIK3CA—stomach cancer	7.18e-05	0.000254	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL8—stomach cancer	7.15e-05	0.000253	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RPS6—stomach cancer	7.11e-05	0.000251	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPP2R1A—stomach cancer	7.06e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HBEGF—stomach cancer	7.03e-05	0.000248	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PRKCB—stomach cancer	6.99e-05	0.000247	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—stomach cancer	6.97e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6ST—stomach cancer	6.96e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TP53—stomach cancer	6.94e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTP1—stomach cancer	6.93e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTHFR—stomach cancer	6.93e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—RHOA—stomach cancer	6.91e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FYN—stomach cancer	6.86e-05	0.000242	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMOX1—stomach cancer	6.83e-05	0.000241	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SMAD4—stomach cancer	6.75e-05	0.000238	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—PIK3CA—stomach cancer	6.7e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6R—stomach cancer	6.69e-05	0.000236	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL8—stomach cancer	6.68e-05	0.000236	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—RHOA—stomach cancer	6.65e-05	0.000235	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—HRAS—stomach cancer	6.64e-05	0.000235	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—MAPK3—stomach cancer	6.6e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HBEGF—stomach cancer	6.53e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL8—stomach cancer	6.49e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TP53—stomach cancer	6.49e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRB2—stomach cancer	6.49e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGFR2—stomach cancer	6.44e-05	0.000228	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TYMS—stomach cancer	6.44e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FYN—stomach cancer	6.41e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CAV1—stomach cancer	6.39e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOA1—stomach cancer	6.37e-05	0.000225	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTM1—stomach cancer	6.37e-05	0.000225	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PPP2R1A—stomach cancer	6.36e-05	0.000224	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—MAPK1—stomach cancer	6.28e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6R—stomach cancer	6.21e-05	0.000219	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—HRAS—stomach cancer	6.2e-05	0.000219	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—RHOA—stomach cancer	6.18e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL8—stomach cancer	6.07e-05	0.000214	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—RHOA—stomach cancer	6.04e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB2—stomach cancer	6.03e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGFR2—stomach cancer	6.02e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ERCC2—stomach cancer	5.99e-05	0.000211	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—KRAS—stomach cancer	5.93e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PPP2R1A—stomach cancer	5.91e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SMAD4—stomach cancer	5.9e-05	0.000208	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS2—stomach cancer	5.9e-05	0.000208	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL8—stomach cancer	5.84e-05	0.000206	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CAV1—stomach cancer	5.72e-05	0.000202	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOA1—stomach cancer	5.71e-05	0.000202	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—stomach cancer	5.63e-05	0.000199	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—stomach cancer	5.62e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RHOA—stomach cancer	5.61e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FYN—stomach cancer	5.6e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS2—stomach cancer	5.51e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SMAD4—stomach cancer	5.48e-05	0.000194	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—stomach cancer	5.45e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCB—stomach cancer	5.44e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—stomach cancer	5.43e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6ST—stomach cancer	5.42e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CAV1—stomach cancer	5.34e-05	0.000189	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOA1—stomach cancer	5.33e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—stomach cancer	5.3e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—stomach cancer	5.27e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGFR2—stomach cancer	5.26e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APC—stomach cancer	5.21e-05	0.000184	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FYN—stomach cancer	5.21e-05	0.000184	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAV1—stomach cancer	5.19e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOA1—stomach cancer	5.18e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCB—stomach cancer	5.08e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6ST—stomach cancer	5.06e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—stomach cancer	5.05e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—HRAS—stomach cancer	5.04e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK3—stomach cancer	4.99e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—stomach cancer	4.93e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR2—stomach cancer	4.89e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APC—stomach cancer	4.87e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6R—stomach cancer	4.84e-05	0.000171	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—stomach cancer	4.83e-05	0.000171	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS2—stomach cancer	4.82e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK1—stomach cancer	4.75e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—stomach cancer	4.75e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CAV1—stomach cancer	4.67e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK3—stomach cancer	4.66e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOA1—stomach cancer	4.66e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—stomach cancer	4.56e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—stomach cancer	4.54e-05	0.00016	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—stomach cancer	4.53e-05	0.00016	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6R—stomach cancer	4.52e-05	0.00016	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—KRAS—stomach cancer	4.48e-05	0.000158	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS2—stomach cancer	4.48e-05	0.000158	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCB—stomach cancer	4.45e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK1—stomach cancer	4.43e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—stomach cancer	4.43e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6ST—stomach cancer	4.43e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—stomach cancer	4.42e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RHOA—stomach cancer	4.37e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CAV1—stomach cancer	4.34e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOA1—stomach cancer	4.33e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—stomach cancer	4.32e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APC—stomach cancer	4.25e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—stomach cancer	4.24e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—stomach cancer	4.23e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—KRAS—stomach cancer	4.19e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCB—stomach cancer	4.13e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—stomach cancer	4.12e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6ST—stomach cancer	4.11e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—stomach cancer	4.1e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RHOA—stomach cancer	4.08e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK3—stomach cancer	4.07e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ERBB2—stomach cancer	4.04e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—stomach cancer	4.04e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APC—stomach cancer	3.95e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6R—stomach cancer	3.95e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—stomach cancer	3.92e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK1—stomach cancer	3.88e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—stomach cancer	3.88e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—stomach cancer	3.85e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—stomach cancer	3.84e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HRAS—stomach cancer	3.81e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK3—stomach cancer	3.79e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ERBB2—stomach cancer	3.78e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1B—stomach cancer	3.75e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—stomach cancer	3.7e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—stomach cancer	3.7e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6R—stomach cancer	3.67e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—KRAS—stomach cancer	3.66e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—stomach cancer	3.65e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK1—stomach cancer	3.6e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—stomach cancer	3.6e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—stomach cancer	3.59e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—stomach cancer	3.58e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—stomach cancer	3.57e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RHOA—stomach cancer	3.57e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JUN—stomach cancer	3.57e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HRAS—stomach cancer	3.56e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—stomach cancer	3.53e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1B—stomach cancer	3.5e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—stomach cancer	3.47e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—stomach cancer	3.46e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—stomach cancer	3.44e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—stomach cancer	3.44e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—stomach cancer	3.41e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—KRAS—stomach cancer	3.4e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK8—stomach cancer	3.37e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—stomach cancer	3.36e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—stomach cancer	3.34e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JUN—stomach cancer	3.33e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RHOA—stomach cancer	3.32e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB2—stomach cancer	3.3e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—stomach cancer	3.28e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—stomach cancer	3.24e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—stomach cancer	3.23e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK8—stomach cancer	3.15e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—stomach cancer	3.13e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—stomach cancer	3.13e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—stomach cancer	3.12e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HRAS—stomach cancer	3.11e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—stomach cancer	3.08e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB2—stomach cancer	3.07e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1B—stomach cancer	3.06e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—stomach cancer	2.98e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK3—stomach cancer	2.95e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—stomach cancer	2.92e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JUN—stomach cancer	2.91e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—stomach cancer	2.91e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—stomach cancer	2.91e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HRAS—stomach cancer	2.89e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—stomach cancer	2.88e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—stomach cancer	2.87e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1B—stomach cancer	2.84e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—stomach cancer	2.83e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—stomach cancer	2.82e-05	9.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK1—stomach cancer	2.8e-05	9.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—stomach cancer	2.8e-05	9.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—stomach cancer	2.77e-05	9.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK8—stomach cancer	2.76e-05	9.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK3—stomach cancer	2.75e-05	9.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—stomach cancer	2.72e-05	9.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—stomach cancer	2.71e-05	9.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JUN—stomach cancer	2.71e-05	9.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—stomach cancer	2.68e-05	9.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KRAS—stomach cancer	2.65e-05	9.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—stomach cancer	2.63e-05	9.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—stomach cancer	2.62e-05	9.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK1—stomach cancer	2.62e-05	9.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—stomach cancer	2.62e-05	9.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK8—stomach cancer	2.56e-05	9.04e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—stomach cancer	2.54e-05	8.99e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—stomach cancer	2.52e-05	8.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KRAS—stomach cancer	2.47e-05	8.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—stomach cancer	2.43e-05	8.59e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK3—stomach cancer	2.41e-05	8.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—stomach cancer	2.36e-05	8.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—stomach cancer	2.35e-05	8.31e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—stomach cancer	2.34e-05	8.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—stomach cancer	2.34e-05	8.27e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK1—stomach cancer	2.29e-05	8.09e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—stomach cancer	2.29e-05	8.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—stomach cancer	2.27e-05	8.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HRAS—stomach cancer	2.25e-05	7.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK3—stomach cancer	2.24e-05	7.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—stomach cancer	2.21e-05	7.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—stomach cancer	2.2e-05	7.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—stomach cancer	2.17e-05	7.68e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KRAS—stomach cancer	2.16e-05	7.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—stomach cancer	2.15e-05	7.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK1—stomach cancer	2.13e-05	7.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—stomach cancer	2.13e-05	7.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HRAS—stomach cancer	2.1e-05	7.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—stomach cancer	2.01e-05	7.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KRAS—stomach cancer	2.01e-05	7.1e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—stomach cancer	1.99e-05	7.02e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—stomach cancer	1.92e-05	6.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—stomach cancer	1.85e-05	6.52e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HRAS—stomach cancer	1.84e-05	6.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—stomach cancer	1.79e-05	6.31e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—stomach cancer	1.76e-05	6.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HRAS—stomach cancer	1.71e-05	6.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—stomach cancer	1.63e-05	5.77e-05	CbGpPWpGaD
